Treating breast cancer in premenopausal Asian women

The international treatment recommendations for women with breast cancer were based on clinical trials from mostly non-Asian women. Therefore, it is controversial whether the universal guidelines are applicable to young Asian women who have distinctive clinicopathological characteristics in breast cancer. The article “Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group (ABCCG) 2019 Consensus and position on ovarian suppression” pointed out the perspective of the ABCCG in treating hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer in premenopausal women. Considering the unique disease characteristics of premenopausal Asian women with breast cancer, the group advocates flexible and individualized use of all potential treatment options instead of rigorously adopting international recommendations. (Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4.)

Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Winne Yeo in the Department of Clinical Oncology, CUHK. Prof Yeo’s research focuses on breast cancer, gastric cancer, Hepatocellular carcinoma, Hepatitis B virus-related complications in cancer patients and Survivorship studies.

Read full article: https://link.springer.com/article/10.1007%2Fs10549-019-05318-5
More about research at CU Medicine: https://research.med.cuhk.edu.hk/